Safety and Efficacy of Systemic Chemotherapy Plus PD-1 Inhibitor in Combination With Bevacizumab in Gastric Cancer With Peritoneal Metastasis

PHASE2Enrolling by invitationINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 1, 2024

Primary Completion Date

March 1, 2025

Study Completion Date

March 1, 2026

Conditions

Gastric Cancer Peritoneal Metastases

Interventions

DRUG

albumin-bound paclitaxel (260 mg/m2, d1)

260 mg/m2, d1)

DRUG

S-1

80 mg/m2, d1-14

DRUG

sintilimab

200 mg, d1

DRUG

bevacizumab

First two cycles : intraperitoneally 7.5 mg/m2 Maintenance period: intravenously 7.5 mg/m2

Trial Locations (1)

Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan

All Listed Sponsors

lead

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

OTHER